“…This strategy deliberately permits additional cycloaddition reactions of the advanced electron-rich dienophile 13 with other reactive heterocyclic azadienes ( 19 – 24 ) for the late-stage, divergent preparation of a series of complementary heterocyclic derivatives (Scheme 4). Representative of this and without individual optimization, this included the reaction of 1,2,3-triazine 13d ( 19 , ALD00112), 22 5-bromo-1,2,3-triazine ( 20 ), 13a 4-carbomethoxy-1,2,3-triazine 13b ( 21 , ALD00104), 22 and 4,6-dicarboethoxy-1,2,3-triazine 13b ( 22 , ALD00110), 22 each of which displayed the 1,2,3-triazine C4/N1 mode of cycloaddition and provided the alternatively substituted pyridines 25 – 28 , 1,3,5-triazine 30 ( 23 ) 22 that provided the pyrimidine 29 , and 3,6-dicarbomethoxy-1,2,4,5-tetrazine 31 ( 24 , ALD00098) 22 that provided the substituted pyridazine 30 and served further as a precursor to the pyrrole 31 via a unique zinc-mediated reductive ring contraction. 32 It is of note that it was the exploration of the ergot alkaloids at Lilly and the preparation of their simplified ring systems that provided the first synthetic use of such heterocyclic azadiene Diels–Alder reactions (use of 30 ) and the first report of the effective zinc-mediated pyridazine to pyrrole reductive ring contraction reaction.…”